COVID-19 Pfizer Information

Thank you for visiting Pfizer Oncology’s Congress Portal at ESMO 2021

Who We Are and What We Do

​​​​​​​One way or another, cancer touches all of our lives. That is why nothing is more personal, or more urgent, than our goal to find new treatments for these deadly diseases


​​​​​​​Thank you for visiting Pfizer Oncology’s Congress Portal at ESMO 2021

Who We Are and What We Do

​​​​​​​One way or another, cancer touches all of our lives. That is why nothing is more personal, or more urgent, than our goal to find new treatments for these deadly diseases

Upcoming Conversations

Symposia

Pfizer’s Sponsored Lung Symposia: Saturday, September 18, 2021 8:45-9:45 CEST

Add To Calendar

Pfizer’s Sponsored Breast Symposia: Saturday, September 18, 2021 10:30-12:00 CEST

Add To Calendar

Pfizer’s Sponsored Multiple Myeloma Symposia: Saturday, September 18, 2021 10:30-12:00 CEST

Add To Calendar

Pfizer’s Sponsored Bladder Symposia: Tuesday, September 21, 2021 10:30-11:45 CEST

Add To Calendar

Live Office Hours

Thursday, September 16, 2021 11:00 AM to 12:00 CEST

Add To Calendar

Monday, September 20, 2021 1:30 PM to 2:30 PM CEST

Add To Calendar

Tuesday, September 21, 2021 1:45 PM to 3:00 PM CEST

Add To Calendar

You have reached the Medical Information department at Pfizer. Personal data that you provide during this call will be processed within the Pfizer group and by our service providers in any country where we or they have facilities. Your personal data will be processed to handle your inquiry or complaint in accordance with our legitimate interests and, where otherwise applicable, to comply with our legal and regulatory obligations around reporting side effects, product complaints and patient safety. Please see our full Privacy Notice, available at https://privacycenter.pfizer.com/inquiries for more information about our privacy practices including how you can contact Pfizer’s data protection officer and request to exercise any rights you may have. If you wish to have a copy, you may request a copy to be sent via email or postal mail.

Connect with Pfizer

Please fill out the form below. A member from the team will respond accordingly.

By providing your email address, you agree to receive an email response from Pfizer to your inquiry. Your email address will only be used to respond to your inquiry. The information you submit will be governed by our Privacy Policy.

All fields marked with an asterisk ( *) are required.

Thank you for
contacting Pfizer.

A team member will respond to your inquiry.

Highlights From Your Congress

 

Pfizer’s Sponsored Lung Symposia

Pfizer’s Sponsored Breast Symposia

Pfizer’s Sponsored Multiple Myeloma Symposia

Pfizer’s Sponsored Bladder Symposia

What’s Of Interest

Learn About Our Oncology Approved Medicines

Biosimilars

NIVESTIM® (filgrastim)

RETACRIT® (epoetin zeta)

RUXIENCE® (rituximab)

Investigator Resources

TRAZIMERA® (trastuzmab)

ZIRABEV™ (bevacizumab)

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

PP-ONC-GLB-0346 Date of preparation September 2021.
​​​​​​​
Full prescribing information of the product is available at the virtual booth under each product tile.

Breast

IBRANCE® (palbociclib)

TALZENNA® (talazoparib)

TRAZIMERA® (trastuzumab)

Investigator Resources

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

PP-ONC-GLB-0346 Date of preparation September 2021.

Full prescribing information of the product is available at the virtual booth under each product tile.

Hematological Malignancies

BESPONSA™ (inotuzumab ozogamicin)

BOSULIF® (bosutinib)

DAURISMO® (glasdegib)

Investigator Resources

MYLOTARG™ (gemtuzumab ozogamicin)

RUXIENCE® (rituximab)

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

PP-ONC-GLB-0346 Date of preparation September 2021.

Full prescribing information of the product is available at the virtual booth under each product tile.

Kidney

BAVENCIO® (avelumab)

INLYTA® (axitinib)

SUTENT® (sunitinib malate)

Investigator Resources

TORISEL® (temsirolimus)

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

PP-ONC-GLB-0346 Date of preparation September 2021.

Full prescribing information of the product is available at the virtual booth under each product tile.

Lung

Lorviqua® (lorlatinib)

VIZIMPRO® (dacomitinib)

VIZIMPRO® (dacomitinib)

XALKORI® (crizotinib)

XALKORI® (crizotinib)

Investigator Resources

ZIRABEV™ (bevacizumab)

ZIRABEV™ (bevacizumab)

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

​​​​​​​PP-ONC-GLB-0346 Date of preparation September 2021.

Full prescribing information of the product is available at the virtual booth under each product tile.

Merkel Cell

BAVENCIO® (avelumab)

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

​​​​​​​PP-ONC-GLB-0346 Date of preparation September 2021.

Full prescribing information of the product is available at the virtual booth under each product tile.

Investigator Resources

Emerging Approaches in Oncology

Focus on Health Equity

Scheduled Events

Oral Presentations


Session title:

Overall survival (OS) from ARCHES: Final analysis of the phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
Oral Presentation No: LBA25
Session Date and Time:
​​​​​​​Saturday,September 18 ,2021
​​​​​​​2:20-2:30 PM CEST


Session title:

PALOMA-4: Primary results from a phase 3 trial of palbociclib (PAL) + letrozole (LET) vs placebo (PBO) + LET in Asian postmenopausal women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breast cancer (ABC)
Mini-Oral Presentation No: 228MO
Session Date and Time:
Saturday,September 18 ,2021
​​​​​​​5:30-5:35 PM CEST


Session title:

Overall Survival (OS) of Palbociclib (P) plus Endocrine Therapy (ET) versus Capecitabine (CAP) in hormone receptor-positive/ HER2-negative metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs). Final results of the PEARL study​​​​​​​
Mini-Oral Presentation No: 229MO
Session Date and Time:
​​​​​​​Saturday,September 18 ,2021
​​​​​​​5:55-6:00 PM CEST


Session title:

Avelumab (A) as the basis of neoadjuvant chemotherapy (NAC) regimen in platinum eligible and ineligible patients (pts) with non-metastatic muscle invasive bladder cancer (NM-MIBC)​​​​​​​
Mini-Oral Presentation No: 659MO
Session Date and Time:
​​​​​​​Saturday, September 18, 2021
6:12 – 6:17 PM CEST


Session title:

Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): first analysis of randomized phase III GORTEC-REACH trial
Oral Presentation No: LBA35
Session Date and Time:
Monday, September 20, 2021
​​​​​​​1:30 – 1:40 PM CEST


Session title:

SECOMBIT: the best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma. A phase II randomized study.
Mini-Oral Presentation No: LBA40
Session Date and Time:
Monday, September 20, 2021
5:55 – 6:00 PM CEST


Session title:

5-year update on COLUMBUS: a randomized phase 3 trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma
Mini-Oral Presentation No: 1041MO
Session Date and Time:
Monday, September 20, 2021
6:00 – 6:05 PM CEST


Session title:

Quality of life from the Penelope-B study on high-risk HR+/HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib
Mini-Oral Presentation No: 122MO
Session Date and Time:
Monday, September 20, 2021
6:07 – 6:12 PM CEST


Session title:

COVID vaccine in cancer patients : Subgroup analysis of safety, immunogenicity and efficacy from a global Phase 3 randomized trial of the BNT162b2 trial
Oral Presentation No: 1558O
Session Date and Time:
Tuesday, September 21, 2021,1:30 – 1: 40 PM CEST


Session title:

The AXINET trial (GETNE1107): Axitinib plus octreotide LAR improves PFS by blinded central radiological assessment vs placebo plus octreotide LAR in G1-2 extrapancreatic NETs
Oral Presentation No: 1098O
Session Date and Time:
Tuesday, September 21, 2021
​​​​​​​ 2:20 – 2:30 PM CEST


Symposia

Pfizer’s Sponsored Lung Symposia: Saturday, September 18, 2021 8:45-9:45 CEST


Pfizer’s Sponsored Breast Symposia: Saturday, September 18, 2021 10:30-12:00 CEST


Pfizer’s Sponsored Multiple Myeloma Symposia: Saturday, September 18, 2021 10:30-12:00 CEST


Pfizer’s Sponsored Bladder Symposia: Tuesday, September 21, 2021 10:30-11:45 CEST


Live Office Hours
​​​​​​​

Thursday, September 16, 2021
11:00 AM to 12:00 PM CEST

Monday, September 20, 2021
1:30 PM to 2:30 PM CEST

Tuesday, September 21, 2021
1:45 PM to 3:00 PM CEST

You have reached the Medical Information department at Pfizer. Personal data that you provide during this call will be processed within the Pfizer group and by our service providers in any country where we or they have facilities. Your personal data will be processed to handle your inquiry or complaint in accordance with our legitimate interests and, where otherwise applicable, to comply with our legal and regulatory obligations around reporting side effects, product complaints and patient safety. Please see our full Privacy Notice, available at EEA Medical Information, Product Complaints and Drug Safety | Pfizer Privacy Notice  for more information about our privacy practices including how you can contact Pfizer’s data protection officer and request to exercise any rights you may have.If you wish to have a copy, you may request a copy to be sent via email or postal mail.

 
 

Commitment To Oncology

Supporting Our Patients

Category list

Category list

X

PF-06863135 is an investigational compound and has not been approved by any Regulatory Authority as safe or effective for any use. The preclinical and in vitro evidence presented here may not necessarily correlate with clinical outcomes.